In May 2026, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) created a dedicated English-language webpage on orphan drug designation. The page is designed to be a central resource for sponsors seeking information on Japan’s orphan drug program, including designation requirements, incentives available and the overall application process.
Under Japan’s orphan drug program, products may qualify for designation if they target a serious disease affecting fewer than 50,000 patients in Japan or a designated intractable disease (“Nan-byo”). Sponsors must also demonstrate a high medical need and have a feasible development plan for Japan. Designated orphan drugs are eligible for a range of incentives, including development subsidies, priority consultation, premium pricing, etc.
The launch of the webpage does not bring any new regulatory requirements or policy changes. However, it provides a clearer and more accessible overview of the orphan drug framework, particularly for companies that may be less familiar with the Japanese regulatory system.
Although largely informational, the new page reflects the PMDA’s ongoing interest in supporting the development of treatments for rare diseases. It also fits in with Japan’s broader efforts to improve access to innovative therapies for patients with limited treatment options.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.